[ใหม่] Tirzepatide Retatrutide TB-500 50-56-6

A clinical trial published in the News Medical Life Sciences showed that tirzepatide led to greater weight loss than semaglutide, with some participants losing up to 22.5% of their body weight. Meanwhile, a National Institute of Diabetes and Digestive and Kidney Issues study highlights the benefits of these drugs for patients with metabolic syndrome. An Institute for Clinical and Economic Review article also highlights the transformative impact of both drugs on obesity treatment worldwide. These medications are now considered among the most promising tools in the medical management of obesity.